Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Femasys Inc. (FEMY), a biomedical company focusing on women's healthcare, announces its participation in the 2024 Maxim Healthcare Virtual Summit. Founder, President, and CEO Kathy Lee-Sepsick will engage in a fireside chat with Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The virtual summit is scheduled for October 15-17, 2024, with Femasys' fireside chat taking place on Thursday, October 17, at 11:00 AM ET. Interested parties can access the webcast through the provided link. Additionally, Kathy Lee-Sepsick and CFO Dov Elefant will be available for one-on-one meetings throughout the summit.
Femasys is known for its broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products addressing significant unmet needs of women worldwide.
Femasys Inc. (FEMY), un'azienda biomedica focalizzata sulla salute delle donne, annuncia la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. La fondatrice, presidente e CEO Kathy Lee-Sepsick parteciperà a una chiacchierata informale con Jason McCarthy, Ph.D., direttore senior e responsabile della ricerca biotecnologica presso Maxim Group.
Il summit virtuale è programmato per 15-17 ottobre 2024, con la chiacchierata di Femasys che si svolgerà giovedì 17 ottobre alle 11:00 AM ET. Le parti interessate possono accedere al webcast attraverso il link fornito. Inoltre, Kathy Lee-Sepsick e il CFO Dov Elefant saranno disponibili per incontri one-on-one durante tutto il summit.
Femasys è conosciuta per il suo ampio portafoglio di prodotti terapeutici e diagnostici innovativi, facilmente accessibili e offerti in ambulatorio, che affrontano significative esigenze insoddisfatte delle donne in tutto il mondo.
Femasys Inc. (FEMY), una empresa biomédica centrada en la salud de las mujeres, anuncia su participación en el 2024 Maxim Healthcare Virtual Summit. La fundadora, presidenta y CEO Kathy Lee-Sepsick participará en una charla informal con Jason McCarthy, Ph.D., director general senior y jefe de investigación biotecnológica en Maxim Group.
La cumbre virtual está programada del 15 al 17 de octubre de 2024, con la charla de Femasys programada para el jueves 17 de octubre a las 11:00 AM ET. Las partes interesadas pueden acceder al webcast a través del enlace proporcionado. Además, Kathy Lee-Sepsick y el CFO Dov Elefant estarán disponibles para reuniones individuales durante toda la cumbre.
Femasys es conocida por su amplio portafolio de productos terapéuticos y diagnósticos innovadores, accesibles y ofrecidos en consultorios, que abordan necesidades no satisfechas significativas de las mujeres en todo el mundo.
Femasys Inc. (FEMY)는 여성 건강에 초점을 맞춘 생명과학 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 창립자이자 CEO인 Kathy Lee-Sepsick는 Maxim Group의 생명공학 연구 책임자인 Jason McCarthy 박사와 비공식 대화에 참여할 예정입니다.
가상 서밋은 2024년 10월 15-17일에 예정되어 있으며, Femasys의 대화는 10월 17일 목요일 오전 11:00 ET에 진행됩니다. 관심 있는 분들은 제공된 링크를 통해 웹캐스트에 접속할 수 있습니다. 또한, Kathy Lee-Sepsick와 CFO Dov Elefant는 서밋 기간 동안 일대일 회의에 참석할 수 있습니다.
Femasys는 전 세계 여성들의 중요한 unmet needs(충족되지 않은 필요)를 해결하는 혁신적이고 접근 가능한 진료실 중심의 치료 및 진단 제품의 폭넓은 포트폴리오로 알려져 있습니다.
Femasys Inc. (FEMY), une entreprise biomédicale axée sur la santé des femmes, annonce sa participation au 2024 Maxim Healthcare Virtual Summit. La fondatrice, présidente et PDG Kathy Lee-Sepsick participera à une discussion informelle avec Jason McCarthy, Ph.D., directeur général senior et responsable de la recherche en biotechnologie chez Maxim Group.
Le sommet virtuel est prévu pour le 15-17 octobre 2024, avec la discussion de Femasys programmée pour le jeudi 17 octobre à 11h00 ET. Les parties intéressées peuvent accéder au webinaire via le lien fourni. De plus, Kathy Lee-Sepsick et le CFO Dov Elefant seront disponibles pour des réunions individuelles tout au long du sommet.
Femasys est connue pour son large éventail de produits thérapeutiques et diagnostiques innovants, accessibles et offerts dans les cabinets médicaux, qui répondent à des besoins importants non satisfaits des femmes dans le monde entier.
Femasys Inc. (FEMY), ein biomedizinisches Unternehmen, das sich auf die Gesundheit von Frauen konzentriert, gibt seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt. Die Gründerin, Präsidentin und CEO Kathy Lee-Sepsick wird in einem informellen Gespräch mit Jason McCarthy, Ph.D., Senior Managing Director und Leiter der Biotechnologieforschung bei Maxim Group, teilnehmen.
Der virtuelle Gipfel ist für den 15.-17. Oktober 2024 geplant, wobei das Gespräch von Femasys am Donnerstag, den 17. Oktober um 11:00 Uhr ET stattfinden wird. Interessierte können über den bereitgestellten Link auf das Webcast zugreifen. Darüber hinaus stehen Kathy Lee-Sepsick und CFO Dov Elefant während des gesamten Gipfels für persönliche Gespräche zur Verfügung.
Femasys ist bekannt für ihr breites Portfolio an innovativen, zugänglichen therapeutischen und diagnostischen Produkten, die in Arztpraxen angeboten werden und bedeutende unerfüllte Bedürfnisse von Frauen weltweit ansprechen.
- None.
- None.
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
| Event: | Fireside Chat at 2024 Maxim Healthcare Virtual Summit |
| Date: | Thursday, October 17, 2024 |
| Time: | 11:00 AM ET |
| Webcast: | https://m-vest.com/events/healthcare-10152024 |
Kathy Lee-Sepsick and Dov Elefant, Chief Financial Officer, will be available for one-on-one meetings throughout the summit.
About Femasys
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe, and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® and FemVue® Mini for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
Matt Blazei
IR@femasys.com
Media:
Kati Waldenburg
Media@femasys.com
FAQ
When is Femasys (FEMY) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Femasys (FEMY) at the 2024 Maxim Healthcare Virtual Summit?
How can investors access the Femasys (FEMY) fireside chat at the Maxim Healthcare Virtual Summit?
What is the focus of Femasys (FEMY) as a biomedical company?
Will Femasys (FEMY) executives be available for one-on-one meetings during the summit?
